IP Library Granted Patent US 7,205,130
Granted Patent B2
US 7,205,130 · App. 10/142,648 · Granted Apr 17, 2007

Bi-directionally cloned random cDNA expression vector libraries, compositions and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,205,130
App. No.
10/142,648
Granted
Apr 17, 2007
Kind
B2
Abstract

The present invention provides random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in sense and antisense orientation, which are useful for the delivery and expression of a combination of genetic effector types to host cells. Methods for producing these libraries through bi-directional cloning of random cDNAs are also provided. Also provided herein are methods of using these libraries to screen for agents capable of modulating cell phenotype in desirable ways.

Claims (12)

1. A method for producing a vector, comprising:

a) contacting an mRNA with a primer under conditions to produce a double-stranded cDNA, said primer having a site for a first restriction endonuclease;

b) cleaving said double stranded cDNA to produce cDNA fragments;

c) ligating a double-stranded adaptor to each end of said cDNA fragments to produce adaptor-modified cDNA, said double stranded adaptor having a site for a second restriction endonuclease;

d) contacting said adaptor-modified cDNA with said first restriction endonuclease and said second restriction endonuclease to produce digested cDNA; and,

e) ligating said digested cDNA into a vector.

2. The method of claim 1 , wherein the double stranded adaptor contains a partial restriction site for said first restriction endonuclease, and wherein a dimer of said double stranded adaptors contains a cleavable restriction site for said first restriction endonuclease.

3. The method of claim 1 , wherein said primer is an oligo-dT primer.

4. The method of claim 1 , wherein said primer is a random primer.

5. The method of claim 1 , wherein said first restriction endonuclease is Not1.

6. The method of claim 1 , wherein said second restriction endonuclease is BstX1.

7. The method of claim 1 , wherein said vector is a retroviral vector.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2002
From: LORENS, JAMES; BOGENBERGER, JAKOB M.
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 013336/0942 →